Scholarlink

<p>Accurate preoperative assessment of hepatic functional reserve (HFR) and future remnant liver function is essential for reducing postoperative morbidity and mortality after liver surgery, yet current clinical methods remain indirect and provide limited spatial and quantitative information. Here, we developed an asialoglycoprotein receptor (ASGPR)-targeted tracer for positron emission tomography (PET), [<sup>68</sup>Ga]Ga-NOTA-lactosylated human serum albumin ([<sup>68</sup>Ga]Ga-NOTA-LSA), and systematically optimized the degree of lactosylation for hepatic imaging. Comparative evaluation of lactosylated human serum albumin constructs bearing 7 or 12 lactose moieties [LSA (7) and LSA (12)] identified LSA (12) as the preferred construct with more favorable hepatocyte targeting in vivo. [<sup>68</sup>Ga]Ga-NOTA-LSA was radiolabeled with high efficiency within 10&#xa0;min at room temperature and showed favorable radiochemical stability in phosphate-buffered saline and serum. The optimized precursor was further formulated as a lyophilized kit, enabling rapid one-step <sup>68</sup>Ga labeling, reproducible preparation, and storage stability. In thioacetamide-induced rat liver fibrosis models, including untreated, spontaneous recovery, and pirfenidone-treated groups, [<sup>68</sup>Ga]Ga-NOTA-LSA PET/CT enabled single-time-point quantitative assessment of hepatic function, with 60&#xa0;min post-injection selected as the optimal imaging time point. Hepatic uptake and liver-to-heart ratios were markedly reduced in fibrotic livers and progressively restored in recovery and treatment models. PET-derived parameters correlated with histological fibrosis, ASGPR expression, fibrogenic and apoptotic markers, and serum liver injury biomarkers. In contrast, <sup>99m</sup>Tc-mebrofenin required serial imaging to evaluate hepatobiliary kinetics, highlighting mechanistic and workflow differences between transport-based scintigraphy and receptor-associated PET uptake imaging. Reduced hepatic uptake was also reproduced in a fibrotic mouse model. In addition, single-dose toxicity testing showed favorable acute tolerability of non-radioactive NOTA-LSA. Together, these findings support the feasibility of [<sup>68</sup>Ga]Ga-NOTA-LSA as a reproducible and quantitative PET platform for HFR imaging with translational potential.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Optimization of 68Ga-lactosylated human serum albumin (LSA) for PET-based quantitative evaluation of hepatic functional reserve in liver fibrosis models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月31日

查看全文
  • Boeun Park,
  • Ji Yong Park,
  • Kisoo Pahk,
  • Jin Sil Kim,
  • Chanmin Joung,
  • Jung Woo Byun,
  • Ran Ji Yoo,
  • Ji Seon Mun,
  • Kyungsil Chae,
  • Jae Min Jeong,
  • Sungeun Kim,
  • Jin Chul Paeng,
  • Yun-Sang Lee

摘要

Accurate preoperative assessment of hepatic functional reserve (HFR) and future remnant liver function is essential for reducing postoperative morbidity and mortality after liver surgery, yet current clinical methods remain indirect and provide limited spatial and quantitative information. Here, we developed an asialoglycoprotein receptor (ASGPR)-targeted tracer for positron emission tomography (PET), [68Ga]Ga-NOTA-lactosylated human serum albumin ([68Ga]Ga-NOTA-LSA), and systematically optimized the degree of lactosylation for hepatic imaging. Comparative evaluation of lactosylated human serum albumin constructs bearing 7 or 12 lactose moieties [LSA (7) and LSA (12)] identified LSA (12) as the preferred construct with more favorable hepatocyte targeting in vivo. [68Ga]Ga-NOTA-LSA was radiolabeled with high efficiency within 10 min at room temperature and showed favorable radiochemical stability in phosphate-buffered saline and serum. The optimized precursor was further formulated as a lyophilized kit, enabling rapid one-step 68Ga labeling, reproducible preparation, and storage stability. In thioacetamide-induced rat liver fibrosis models, including untreated, spontaneous recovery, and pirfenidone-treated groups, [68Ga]Ga-NOTA-LSA PET/CT enabled single-time-point quantitative assessment of hepatic function, with 60 min post-injection selected as the optimal imaging time point. Hepatic uptake and liver-to-heart ratios were markedly reduced in fibrotic livers and progressively restored in recovery and treatment models. PET-derived parameters correlated with histological fibrosis, ASGPR expression, fibrogenic and apoptotic markers, and serum liver injury biomarkers. In contrast, 99mTc-mebrofenin required serial imaging to evaluate hepatobiliary kinetics, highlighting mechanistic and workflow differences between transport-based scintigraphy and receptor-associated PET uptake imaging. Reduced hepatic uptake was also reproduced in a fibrotic mouse model. In addition, single-dose toxicity testing showed favorable acute tolerability of non-radioactive NOTA-LSA. Together, these findings support the feasibility of [68Ga]Ga-NOTA-LSA as a reproducible and quantitative PET platform for HFR imaging with translational potential.

Graphical abstract